Regeneron Publishes the Results of REGEN-COV (casirivimab and imdevimab) in P-III Trial for COVID-19 in NEJM
Shots:
- The P-III trial evaluates the efficacy and safety of REGEN-COV (casirivimab and imdevimab- 1200/2400mg) vs PBO in a non-hospitalized patient with COVID-19
- The trial met its 1EPs & 2EPs i.e.- 70% reduction in the risk of hospitalization or death in high-risk non-hospitalized patients & the safety profile was consistent with a previously reported data
- Additionally- multiple analyses showed that the Ab cocktail retains potency against the variants of concern circulating within the US. REGEN-COV is available for free to eligible patients in the US as part of a US government-funded program
| Ref: PR Newswire | Image: The Print
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com